Evidence map›Paper›PMID 41189641›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)

Early Alzheimer's disease patient care pathway and health system readiness: A framework for integrated care.

Ilya M Nasrallah, Cate Polacek, Feride H Frech, Pierre N Tariot, Jeff Vawter, Yuval Zabar, Christine Divers, Whoy Y Shang, David S Geldmacher, Michele Towman and 7 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The value of timely treatment with anti-amyloid therapy for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Bridging the diagnostic gap: Expanding dementia care navigation for timely diagnosis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ilya M NasrallahDepartment of Radiology University of Pennsylvania Hospital Philadelphia Pennsylvania USA.
Cate PolacekApplied Sciences Premier Inc. Charlotte North Carolina USA.ORCID https://orcid.org/0000-0001-7352-9325
Feride H FrechUS Neurology Medical Affairs Eisai Inc. Nutley New Jersey USA.
Pierre N TariotBanner Alzheimer's Institute University of Arizona College of Medicine Phoenix Arizona USA.
Jeff VawterApplied Sciences Premier Inc. Charlotte North Carolina USA.
Yuval ZabarGlobal Medical Affairs Biogen Inc. Cambridge Massachusetts USA.
Christine DiversUS Neurology Medical Affairs Eisai Inc. Nutley New Jersey USA.
Whoy Y ShangDepartment of Geriatrics Norton Healthcare Louisville Kentucky USA.
David S GeldmacherCallahan Eye Hospital University of Alabama at Birmingham Birmingham Alabama USA.
Michele TowmanUS Neurology Medical Affairs Eisai Inc. Nutley New Jersey USA.
Heather ReiterApplied Sciences Premier Inc. Charlotte North Carolina USA.
Cindy D MarshallAT&T Memory Center Baylor Scott & White Health Dallas Texas USA.
Valeria BaldiviesoMedical Group Memory Care at Innovation Tower AdventHealth Orlando Florida USA.
Daryl Rhys JonesUS Neurology Medical Affairs Eisai Inc. Nutley New Jersey USA.
Erik S MusiekDepartment of Neurology Washington University St. Louis Missouri USA.
Hideki ToyosakiUS Neurology Medical Affairs Eisai Inc. Nutley New Jersey USA.
Babak TousiLou Ruvo Center for Brain Health Cleveland Clinic Cleveland Ohio USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is often underdiagnosed, especially at early stages when symptoms are mild, and patients may benefit from new and recently approved anti-amyloid therapies. An updated patient care pathway may facilitate timely diagnosis and intervention. We conducted a scan of published information and convened an expert panel of health care professionals to gain insights on early AD care pathways. We developed an Early AD Patient Care Pathway as an implementation guide that includes new diagnostic and treatment modalities and addresses needs and opportunities. The Early AD Patient Care Pathway focuses on patient identification, assessment, diagnosis, treatment, and management and monitoring. Operational readiness considerations aid pathway implementation and include evaluating and addressing gaps in program and business planning, technology, education and resources, access and reimbursement, and care coordination. The pathway is adaptable to health system needs and may be further tested and refined for sustainability. Highlights: We analyzed published information and insights from subject matter experts on care pathways for early Alzheimer's disease.We identified opportunities to improve screening of at-risk patients, make appropriate specialist referrals, and ensure timely access and care coordination for diagnosis, treatment, and monitoring as a means of incorporating the latest diagnostics and therapy options.We developed a care pathway that promotes an integrated approach to patient care and is adaptable to various healthcare settings with input from subject matter experts.

Indexed as

care coordinationcare pathwayearly Alzheimer's diseaseearly identificationmild cognitive impairment

Identifiers

PMID41189641
PMCPMC12580852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.